A heavyweight consortium of Chinese biomedical- and healthcare-focused funds said it would acquire San Diego-based biotech Ambrx, which abandoned an initial public offering last year, in a deal that opens a path to cutting-edge candidates in oncology therapies.
WuXi PharmaTech, China's largest CRO, again boosted its revenue by double digits last quarter, keeping the pace of growth as it considers an offer to go private.
WuXi PharmaTech, China's largest CRO, is considering an offer that would take it private at a sizable premium, forming a committee of independent advisers as it plots its next move.
Wuxi PharmaTech, which is making a big push into cell line manufacturing, has started work on a $150 million plant in China, after already starting on new facilities in the U.S.
WuXi Biologics is embarking on construction of what will be the biggest biologics plant in China once it's completed--an event the company expects by the end of next year.
WuXi Biologics said it has begun construction of a $150 million manufacturing facility for its biologics unit, which it lists as being the largest biologics manufacturing facility of any kind in China.
WuXi PharmaTech's CEO has teamed up with a major investor in an attempt to take the CRO private, pitching a buyout that would give the Chinese company's shareholders a 16.2% premium.
Months removed from buying its way into the world of Big Data genomics, Chinese CRO WuXi PharmaTech has partnered up with DNAnexus to take its technology to the cloud.
WuXi PharmaTech's WuXi NextCODE Genomics unit is teaming up with DNAnexus to offer cloud-based genomic services, leveraging WuXi NextCODE's genome analytic technology and DNAnexus' cloud-based platform to facilitate R&D and expand the companies' global footprint.
Shanghai-based WuXi PharmaTech said its subsidiary WuXi NextCODE Genomics has joined with U.S.-based DNAnexus to offer a wider range of genomics services worldwide, including cloud-based services, according to a press release on Wednesday.